KENDLE INTERNATIONAL INC
8-K, 1997-09-18
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: ALLIANCE GREATER CHINA 97 FUND INC, 497, 1997-09-18
Next: OHIO STATE FINANCIAL SERVICES INC, 10QSB, 1997-09-18



                       SECURITIES AND EXCHANGE COMMISSION


                             Washington, D.C. 20549


                                    FORM 8-K


                                 CURRENT REPORT



     PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934


       Date of Report (Date of earliest event reported) September 3, 1997



                            KENDLE INTERNATIONAL INC.
- --------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)


         Ohio                         000-23019                  31-1274091
- --------------------------------------------------------------------------------
(State or other jurisdiction          (Commission               (IRS Employer
     of incorporation)                File Number)           Identification No.)


      441 Vine Street, Suite 700, Cincinnati, Ohio                    45202
- --------------------------------------------------------------------------------
        (Address of principal executive offices)                     Zip Code


Registrant's telephone number, including area code  (513) 381-5550



- --------------------------------------------------------------------------------
         (Former name or former address, if changed since last report.)






<PAGE>




Item 2.        Acquisition or Disposition of Assets.

               On September 3, 1997,  the Registrant  acquired GMI  Gesellschaft
fur Angewandte Mathematik und Informatik mbH ("gmi"), based in Munich,  Germany.
The cost of the  acquisition  was  approximately  $9,326,000 in cash and 191,304
shares of Common Stock of the  Registrant  valued at the August 22, 1997 initial
public  offering  price of $14 per  share.  The cash was  provided  from the net
proceeds of the  Company's  August 22, 1997  initial  public  offering of common
stock.

        Founded in 1983, gmi provides a wide range of clinical drug  development
services  including Phase II to Phase IV clinical trials and has experience in a
variety of national and international  projects across a wide range of diseases.
gmi also  engages  in  scientific  consulting,  the  planning,  realization  and
evaluation  of health  economic  studies and also  conducts  seminars,  in-house
training programs and presentations.  gmi operates primarily in Germany, but has
conducted  trials in six  additional  countries  including  Austria,  the United
Kingdom,  Switzerland  and France.  In 1996, gmi  participated in 119 studies at
multiple  sites and recorded net revenues of $7.0  million,  a 32% increase over
the prior year,  and operating  profit of $1.4 million,  a 16% increase over the
prior year.

     Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

          (a)  Financial Statements:

               Balance  Sheets as of December  31,  1995 and 1996;  and June 30,
               1997 (Unaudited)

               Statements  of Operations  for the years ended  December 31, 1995
               and 1996;  and for the six months  ended  June 30,  1996 and 1997
               (Unaudited)

               Statements of Changes in Shareholders' Equity for the years ended
               December 31, 1995 and 1996; and for the six months ended June 30,
               1997 (Unaudited)

               Statements  of Cash Flows for the years ended  December  31, 1995
               and 1996;  and for the six months  ended  June 30,  1996 and 1997
               (Unaudited)

          (b)  Pro Forma Financial Information

          (c)  Exhibits

               10.  Share Purchase Agreement Dated July 2, 1997 by and among the
                    Registrant  and   Shareholders  of  GMI   Gesellschaft   fur
                    Angewandte Mathematik und Informatik mbH

               23.  Consent of Coopers & Lybrand GmbH

     The  financial   statements  and  pro  forma   financial   information  are
incorporated  by reference to the  prospectus  filed  pursuant to Rule 424(b) to
Registration  Statement No. 333-30581 beginning on Page F-18 with respect to the
financial  statements  and  beginning  on Page 18 with  respect to the pro forma
financial  information.  Exhibit 10 is incorporated by reference to Registration
Statement No. 333-30581.


                                            - 2 -

<PAGE>



                                          SIGNATURES


        Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                           KENDLE INTERNATIONAL INC.



Date:  September 18, 1997                  By: /s/Timothy M. Mooney
                                              ---------------------
                                                Timothy M. Mooney
                                                Vice President - 
                                                Chief Financial Officer



                                            - 3 -







                              CONSENT OF INDEPENDENT ACCOUNTANTS


        We consent to the  incorporation by reference in this report on Form 8-K
of our report dated May 7, 1997, on our audit of the financial statements of gmi
gesellschaft fur angewandte mathematik und informatik mbH, Munich as of December
31, 1996 and 1995,  and for each of the two years in the period  ended  December
31,  1996,  appearing  in the  registration  statement on Form S-1 (SEC File No.
333-30581) of Kendle  International  Inc. filed with the Securities and Exchange
Commission pursuant to the Securities Act of 1933.





Coopers & Lybrand
Wirtschaftsprufungsgesellschaft GmbH


Munich, Germany
September 16, 1997




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission